Accumulation of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts is a hallmark of tumor-associated inflammation, which is thought to be a barrier to im- Moreover, we found that, in addition to the tumor cells, tumor-infiltrated CD11b + myeloid cells also expressed CXCL1 and CXCL2. Furthermore, CXCL1-and CXCL2-induced increase of mo-MDSC was not correlated with chemotaxis, proliferation or apoptosis of mo-MDSC. These findings show a novel role of CXCL1 and CXCL2 in promoting mo-MDSC generation by favoring the differentiation of bone marrow cells in tumor-bearing conditions, which suggests that inhibition of CXCL1 and CXCL2 could decrease mo-MDSC generation and improve host immunosurveillance.
K E Y W O R D S

CD11b
+ myeloid cell, CXCL1, CXCL2, differentiation, mo-MDSC suppression of T-cell function. 3, 4 In addition to immunosuppression, MDSC are also reported to promote tumor metastasis by constructing a premetastatic niche. 5 MDSC are a heterogeneous population consisting of myeloid progenitor cells and immature myeloid cells. Hematopoiesis is a coordinated process that is well controlled by multiple factors, such as cytokines secreted by activated immune cells or stromal cells, as well as cells from organs, such as the liver and kidney. 7 In physiological conditions, immature myeloid cells are mainly derived from hematopoietic stem cells (HSC) in bone marrow and differentiated into mature immune cells, such as granulocytes, monocytes and macrophages. 8 In pathological situations, such as with a tumor, acute or chronic inflammation and trauma, along with the changed expression profile of cytokines, the pathways of differentiation from HSC are partially blocked, which results in excessive expansion of MDSC. 6, 9 Studies have shown that the factors implicated in the expansion and activation of MDSC could be divided into two main groups. One group consists of the factors mainly produced by tumor cells, which induce MDSC expansion by promoting myelopoiesis and inhibiting differentiation into mature myeloid cells.
The other group consists of the factors primarily produced by tumor stromal cells, which are involved in the activation of MDSC. 6 Numerous studies have reported the immunosuppressive mechanism of MDSC, whereas the expansion mechanism of MDSC is still poorly elucidated. It has been reported that tumor-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) drives the development of MDSC in mouse models of pancreatic ductal adenocarcinoma and breast carcinoma. 10, 11 In addition to GM-CSF, the combination of G-CSF and interleukin (IL)-6 leads to a rapid generation of MDSC from precursors in the bone marrow. 12 Vascular endothelial cell growth factor (VEGF), stem cell factor (SCF) and IL-1β are also reported to drive the expansion of MDSC. 13, 14 It is well known that the development of MDSC not only involves the expansion of MDSC but also requires the activation of immunosuppression. IL-4
and IL-13 were found to be involved in the upregulation of arginase 1. 15 In addition, interferon (IFN)-γ also increases the immunosuppression of MDSC. IL-18 has been found to not only differentiate CD11b − bone marrow progenitor cells into mo-MDSC but also to enhance the immunosuppressive responses of MDSC. 16 In addition to the reported growth factors and cytokines, chemokines CXCL16
and CCL21 are also reported to induce MDSC expansion and thereby contribute to the failure of T-cell immunosurveillance. 17, 18 Chemokine (C-X-C motif) ligand 1 (CXCL1) and chemokine (C-X-C motif) ligand 2 (CXCL2), which are 90% identical in amino acid sequence and share the same receptor, CXCR2, have been extensively studied with regard to their role in recruiting neutrophils. 19, 20 Herein, we identified CXCL1 and CXCL2 as novel factors in promoting mo-MDSC generation from bone marrow cells, and knock down of CXCL1 or CXCL2 decreased the percentage of mo-MDSC.
We found that CXCL1 and CXCL2 were secreted by tumor cells and 
| Reagents and antibodies
| Flow cytometry analysis
Bone marrow and spleen were ground and filtered through a 100- 
| T-cell proliferation assay
The T-cell proliferation assay was carried out as previously described. 21 Splenocytes ( 
| In vivo mo-MDSC induction assay
Conditioned medium was collected from the serum-free medium cultured with B16F10 cells, 4T1 cells and MEF cells for 18 hours.
For in vivo induction experiments, the collected supernatant was concentrated at 300 g for 20 minutes at 4°C using a 3000 nominal molecular-weight limit centrifugal filter (Merck Millipore, Burlington, MA, USA). The concentrated cell-conditioned medium (300 μL) was injected i.v. daily for 7 days in the absence or presence of CXCL1
(50 μg/mouse) or CXCL2 (50 μg/mouse).
| Cytokine array for cell-conditioned medium
For the cytokine array, the conditioned medium collected from B16F10 cells, 4T1 cells and MEF cells was processed according to the manufacturer's instructions (R&D Systems).
| Induction of mouse bone marrow cells in vitro
Induction of mouse bone marrow cells was carried out as previously described. 22 Briefly, mouse bone marrow cells were flushed out from the femurs and tibias using a syringe with a 26-gauge needle and ground into a single-cell suspension. Erythrocytes were eliminated using hypotonic lysis buffer. The remaining cells were cultured in complete medium supplemented with GM-CSF (10 ng/mL) for 5 days. In a separate experiment, CXCL1 or CXCL2 was added to the induction system. injected into mice four times every other day.
| Cell isolation
Monocytic MDSC and G-MDSC were sorted by using the AutoMACS sorter (Miltenyi Biotech) with a myeloid-derived sup- and 5′-CTCTCTTGCGGACCATCTCC-3′ for iNOS. Primers used for the housekeeping gene actin were 5′-AACAGTCCGCCTAGAAGCAC-3′
and 5′-CGTTGACATCCGTAAAGACC-3′. D,E, Percentages and numbers of mo-MDSC in the bone marrow and spleen from normal mice and tumor-bearing mice were analyzed; n ≥3. F, Expression of Ki-67 in mo-MDSC from the blood, bone marrow and spleen of normal mice and tumor-bearing mice was assessed by flow cytometry. *P < .05; **P < .01; ***P < .0001; n.s means no significance the lower wells. Based on the size of the cells, a 5-μm pore transwell chamber was used for mo-MDSC, and a 3-μm pore was used for G-MDSC. The migrated cells were collected in the lower chamber and calculated after incubation at 37°C with 5% CO 2 for 3 hours.
| Transwell analysis
| Statistical analysis
The data were analyzed by Student's t test using GraphPad Prism software.
F I G U R E 2 Tumor cell-secreted cytokines induce the expansion of monocytic myeloid-derived suppressor cells (mo-MDSC).
A, Numbers of mo-MDSC in the blood, bone marrow and spleen were analyzed by flow cytometry after normal mice were i.v. injected with cell-free media (Media), B16F10-conditioned media (B16F10-CM) or mouse embryo fibroblast (MEF)-conditioned media (MEF-CM); n ≥3. B, Numbers of mo-MDSC in the blood, bone marrow and spleen in normal mice, tumor-bearing mice and tumor-removed tumor-bearing mice were analyzed by flow cytometry (Norm/surg, normal mice with surgery; TB, tumor-bearing mice; TB/surg, tumor-bearing mice with tumor-removing surgery); n ≥3. The primary tumor in the tumor-bearing mice was surgically removed after s.c. inoculation for 3 weeks, and the number of mo-MDSC was detected 2 weeks later. C, Mo-MDSC were generated by culturing bone marrow cells in the presence of 10 ng/mL GM-CSF for 5 days in vitro, and the induced mo-MDSCs were isolated and then cocultured with T cells to examine the proliferation of T cells by flow cytometry; left, differentiated mo-MDSC from bone marrow in vitro; middle, representative graph showing suppression of T-cell proliferation; right, quantitative analysis of the percentage of proliferative T cells (stim., stimulation with anti-CD3/CD28 antibodies). D, Percentages of mo-MDSC from the bone marrow were analyzed after induction of bone marrow cells using cell-free media (Media) or conditioned medium from the culture of MEF cells (MEF-CM), B16F10 cells (B16F10-CM) and 4T1 cells (4T1-CM) for the indicated days. **P < .01; ***P < .0001; n.s means no significance
| RE SULTS
| Monocytic MDSC expand under tumor-bearing conditions
Tumor progression is often accompanied by immunity and inflammation, and the immune system is altered by the tumor environment. 1 To test the effect of tumors on immune cells, we examined 
| Tumor cells highly express CXCL1 and CXCL2
To identify the tumor-secreted factors that contribute to the generation of mo-MDSC from bone marrow cells, we conducted analyzed by flow cytometry after CXCL1, CXCL2 or CXCL10 was given to our in vitro mo-MDSC induction system for 5 days in the presence of GM-CSF; right, quantitative analysis. H,I, Mice were i.v. injected with B16F10 tumor cell-conditioned media (TCM) in the absence or presence of CXCL1 or CXCL2, and the numbers of mo-MDSC and G-MDSC in the blood, bone marrow and spleen were analyzed. *P < .05; ***P < .0001; n.s means no significance a cytokine array analysis by using conditioned medium from MDSC from the blood and tumor was analyzed after the B16F10 cells, shCXCL1 B16F10 cells, shCXCL2 B16F10 cells and shCtrl B16F10 cells were s.c. inoculated into mice for 3 weeks. F, Conditioned medium was collected after CXCL1 or CXCL2 was knocked down in B16F10 cells, and proportion of mo-MDSC was analyzed by flow cytometry after culturing the bone marrow cells with the collected medium; right, quantitative analysis. *P < .05; **P < .01; ***P < .0001; n.s means no significance the expression level was different between them ( Figure 3A ,B).
Of note, we found that in the medium from both B16F10 cells and 4T1 cells, CXCL1 and CXCL2 were more highly expressed than in the medium of MEF cells ( Figure 3A ,B), which was confirmed by the real-time PCR results ( Figure 3C ). Furthermore, melanocytes and breast epithelial cells were separated from mice ( Figure   S3 ), and the expression of CXCL1 and CXCL2 in melanocytes and breast epithelial cells was significantly lower than in B16F10 and 4T1 ( Figure S4 ).
Besides tumor cells, high-level expressions of CXCL1 and
CXCL2 were also detected in the primary tumor of B16F10-bearing mice ( Figure 3D) . Furthermore, the expression levels of CXCL1 and CXCL2 in human carcinoma samples were obtained from the cancer microarray database, Oncomine. 27 The data showed that CXCL1 and CXCL2 were more highly expressed in carcinomas than in normal tissue samples in multiple carcinoma types, such as melanoma, head and neck cancer and brain and central nervous system (CNS) cancer ( Figure 3E ). Together, these data indicate that CXCL1 and CXCL2 were highly expressed in tumor cells, and their expression was widely distributed in clinical carcinoma samples.
| Giving CXCL1 and CXCL2 increases the generation of mo-MDSC both in vivo and in vitro
As the conditioned medium from B16F10 cells and 4T1 cells could trigger the accumulation of mo-MDSC, and CXCL1 and CXCL2 were specifically expressed in B16F10 cells and 4T1 cells, we therefore presumed that CXCL1 and CXCL2 were associated with the expansion of mo-MDSC. Recombinant CXCL1 or CXCL2 was given in our in vitro induction assay. In the negative control group, bone marrow cells were treated with equal concentrations of CXCL10. The data showed that CXCL1 and CXCL2 promoted the differentiation of bone marrow cells into mo-MDSC ( Figure 3F ) rather than into G-MDSC ( Figure 3G) . isolated from the primary tumor, spleen and blood was tested, and the expression of CXCL1 and CXCL2 in a heterogeneous primary tumor was used as a control. D, Tumor-bearing mice were i.v. injected with shCXCL1 or shCXCL2 lentivirus, and the numbers of mo-MDSC in the blood and bone marrow were assessed by flow cytometry; n≥ 4. **P < .01; ***P < .0001
Importantly, the increased levels of mo-MDSC were only detected in the blood and bone marrow, rather than in the spleen, suggesting that the CXCL1 and CXCL2 administration-induced increase of mo-MDSC in blood mainly derived from bone marrow. In addition, increased G-MDSC in blood and decreased G-MDSC in bone marrow were found, further verifying the function of CXCL1 and CXCL2 in recruiting G-MDSC ( Figure 3I) . Moreover, the number of G-MDSC in spleen was not affected by giving CXCL1 and CXCL2 ( Figure 3I ).
| Knockdown of CXCL1 or CXCL2 attenuates the expansion of mo-MDSC
To further identify the function of CXCL1 and CXCL2 in promoting the expansion of mo-MDSC, we knocked down CXCL1 or CXCL2 in B16F10 cells using shRNA technology. The data showed that the silencing of CXCL1 or CXCL2 expression did not influence the cell growth kinetics ( Figure S5) . Then, the above cells were s.c. implanted
Chemokine (C-X-C motif) ligand 1 (CXCL1) or CXCL2 knockdown-induced decrease in monocytic myeloid-derived suppressor cells (mo-MDSC) is not related to their chemotaxis, proliferation or apoptosis. A, Granulocytic MDSC (G-MDSC) and mo-MDSC were isolated from the blood and bone marrow of tumor-bearing mice, and the chemotaxis of G-MDSC and mo-MDSC to CXCL1 and CXCL2 was assessed using a transwell assay. Chemotaxis of isolated mo-MDSC from the blood to CCL12 was used as a positive control. B, Expression of C-X-C chemokine receptor type 2 (CXCR2) on G-MDSC and mo-MDSC in the blood and bone marrow was analyzed by flow cytometry. C, Expression of Ki-67 in mo-MDSC from the blood and bone marrow was assessed by flow cytometry. D, Percentage of Ki-67-positive mo-MDSC from the bone marrow was quantitatively analyzed by flow cytometry after the mice were s.c. inoculated with B16F10 cells, CXCL1 ShRNA-transferred (shCXCL1) B16F10 cells,CXCL2 ShRNA-transferred (shCXCL2) B16F10 cells and control ShRNA-transferred (shCtrl) B16F10 cells (left) or tumor-bearing mice were i.v. injected with shCXCL1 or shCXCL2 lentivirus (right). E, Annexin V expression of mo-MDSC from the blood and bone marrow was assessed by flow cytometry; n ≥3. F, Percentage of apoptotic mo-MDSC from the blood was quantitatively analyzed by flow cytometry after the mice were s.c. inoculated with B16F10 cells, shCXCL1 B16F10 cells, shCXCL2 B16F10 cells and shCtrl B16F10 cells (left) or tumor-bearing mice were i.v. injected with shCXCL1 or shCXCL2 lentivirus (right). *P < .05; **P < .01; n.s means no significance into normal mice, and the mice were examined at the indicated time points. Beginning from the 14th day, the number of mo-MDSC in the blood of shCXCL1 or shCXCL2-bearing mice was decreased, compared with that of the WT and shCtrl-bearing mice, and this tendency was maintained until the 21st day ( Figure 4A) . Also, the number of mo-MDSC in the bone marrow was decreased in the 3rd week ( Figure 4B ).
We also analyzed the accumulation of mo-MDSC in the primary tumor when CXCL1 or CXCL2 were knocked down. Consistent with the decreased mo-MDSC in blood and bone marrow, the number of mo-MDSC in primary tumor was also decreased ( Figure 4C ). Moreover, a decreased number of G-MDSC was observed ( Figure 4C ), which was in line with the fact that CXCL1 and CXCL2 were chemoattractants of G-MDSC. In addition, we found that the knockdown of CXCL1 or CXCL2 in B16F10 cells delayed the growth of primary tumor ( Figure 4D ). In response to the inhibition of tumor growth, the number of G-MDSC in the blood and bone marrow of shCXCL1-or shCXCL2-bearing mice was obviously decreased from the 3rd week after tumor cell inoculation ( Figures S6 and S7 ). In addition, there was no significant relevance between the immunosuppressive activity of mo-MDSC and CXCL1
or CXCL2 ( Figure 4E ). 
| Chemokine (C-X-C motif) ligand 1 and CXCL2 do not impact chemotaxis, proliferation or apoptosis of mo-MDSC
As a reduced recruitment of mo-MDSC was detected in the primary tumor when CXCL1 or CXCL2 were knocked down and CXCL1
and CXCL2 were initially discovered as chemokines to recruit CD11b + Ly6G + cells, 20 a transwell assay was conducted to examine whether CXCL1 and CXCL2 also recruit mo-MDSC. CCL12 was used as a positive control. 28 Data showed that CXCL1 and CXCL2 could recruit G-MDSC, but not mo-MDSC, regardless of whether the mo-MDSC were isolated from the blood or the bone marrow ( Figure 6A ).
In addition, G-MDSC, but not mo-MDSC, expressed high levels of CXCR2 ( Figure 6B ). Taken together, these results suggest that the decrease in the levels of mo-MDSC detected in the blood was not related to the chemotaxis of mo-MDSC. Furthermore, mo-MDSC isolated from the primary tumor did not express CXCR2 ( Figure S11 ), indicating that the reduced recruitment of mo-MDSC in the primary tumor of shCXCL1-or shCXCL2-bearing mice did not result from knockdown of CXCL1 or CXCL2.
Proliferation and apoptosis of mo-MDSC were also examined.
Data showed that mo-MDSC from the bone marrow, but not from the blood, have proliferative activity ( Figure 6C ). Similar results were obtained by examining the cell-cycle profile ( Figure S12 ).
Lung recruited-mo-MDSC were used as a negative control, which was reported without proliferation potential. 29 Moreover, there was greater Ki-67 expression in mo-MDSC from the bone marrow of B16F10-bearing mice than that from normal mice ( Figure 6D ).
In addition, mo-MDSC from the blood showed obvious apoptosis, and no apoptosis of mo-MDSC from the bone marrow was detected ( Figure 6E) . Additionally, the apoptosis of mo-MDSC in blood were not affected by the interference of CXCL1 or CXCL2 ( Figure 6F ).
Together, these results suggest that CXCL1 and CXCL2 do not affect the chemotaxis, proliferation or apoptosis of mo-MDSC. GM-CSF administration. 24, 25 CXCL1 and CXCL2 are expressed at low levels in homeostatic conditions, whereas in inflammatory conditions, they are highly produced by a number of different cells, 20 and their expression levels are primarily regulated by growth factors/mediators, such as VEGF, transforming growth factor (TGF)β, JNK, and PI3K. 33, 34 Extensive expression of CXCL1 and CXCL2 in tumor tissue has been reported. 35 In a tumor microenvironment, CXCL1 and CXCL2 are not only expressed in tumor cells but also in endothelial cells and epithelial cells. 36, 37 In our work, we found that in addition to tumor cells, tumor-infiltrated CD11b + myeloid cells also contributed to the expression of CXCL1 and CXCL2 ( Figure 5C ). Furthermore, these myeloid cells in the blood and spleen expressed almost undetectable levels of CXCL1 and CXCL2 ( Figure 5C ), implying that the tumor microenvironment could transform the recruited myeloid cells and make them beneficial for tumor progression.
| D ISCUSS I ON
So, we reported a new source of CXCL1 and CXCL2 in the tumor microenvironment.
The expansion of immune cells involves several aspects, including differentiation from progenitor cells, increased proliferation and decreased apoptosis. 38 CXCR2 has been reported to be involved in the proliferation of T cells. 39 Our results showed that CXCL1 and CXCL2 had no effect on the proliferation of mo-MDSC ( Figure 6D . 38 Therefore, the exact precursors that CXCL1 and CXCL2 act on remain to be further explored.
Recently, CXCR2 was reported to be differentially expressed in 
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